Finanzen von Niagen Bioscience Inc (NAGE)NAGENiagen Bioscience Inc

Niagen Bioscience Inc (NAGE) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Consumer Products Segments, accounting for 81.1% of total sales, equivalent to $24.16M. Other significant revenue streams include Ingredients Segments and Corporate and other. Understanding this composition is critical for investors evaluating how NAGE navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Niagen Bioscience Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of 13.32%, provide a clear picture of how effectively NAGE converts its operational activities into shareholder value.

In the context of the broader market, NAGE competes directly with industry leaders such as ARTV and NATR. With a market capitalization of $166.57M, it holds a significant position in the sector. When comparing efficiency, NAGE's gross margin of N/A stands against ARTV's N/A and NATR's 72.86%. Such benchmarking helps identify whether Niagen Bioscience Inc is trading at a premium or discount relative to its financial performance.

The company reported a gross margin of 64.84% in Q2 2026, indicating strong profitability, but revenue has shown volatility with a recent decline to $29.8 million, falling short of expectations.